Biweekly GLP-1 Injection Shows Promise for Blood Sugar Control and Weight Management

A new biweekly injection, bofanglutide, has shown significant potential in managing blood sugar levels and promoting weight loss among individuals with type 2 diabetes, according to findings from a phase 2b clinical trial. Unlike established GLP-1 medications such as Ozempic and Wegovy, which are administered once a week, this innovative treatment requires injections only every two weeks, making it an appealing option for those who are apprehensive about frequent needles.

Conducted across 37 sites in China, the trial involved 272 adult participants with an average age of approximately 51 years. Participants were randomly assigned to five different treatment groups, which included varying dosages of bofanglutide (12 mg, 18 mg, and 24 mg biweekly), a once-weekly bofanglutide group, and a comparison group receiving semaglutide, a widely used GLP-1 medication.

The primary focus of the study was to evaluate changes in HbA1c levels—an important marker for long-term blood sugar control—over a 24-week period. Results indicated that all groups receiving bofanglutide experienced marked reductions in blood sugar levels. Additionally, these participants also reported weight loss and improvements in several cardiometabolic risk factors, underscoring the medication’s potential benefits beyond glucose management.

When comparing bofanglutide to semaglutide, the findings revealed that blood sugar reductions among bofanglutide users were sometimes greater than those observed in the semaglutide group. However, it is important to note that the semaglutide group received a relatively low dosage, necessitating further research to determine the overall effectiveness of bofanglutide compared to its counterpart.

Experts in the field are cautiously optimistic about the results. Dr. Mir Ali, a medical director specializing in weight management, emphasized the need for more extensive real-world studies to establish whether bofanglutide could surpass semaglutide in effectiveness. Meanwhile, Dr. Clare Thompson, a general practitioner, pointed out the study’s limitations, including its small sample size and the specific demographic of participants, which may not represent broader populations, particularly those in Western countries.

As with other GLP-1 medications, bofanglutide may lead to side effects such as gastrointestinal issues, including nausea, vomiting, diarrhea, and constipation. While these symptoms were reported to be more frequent with the new medication, they were generally mild. Injection site reactions, such as swelling or discomfort, may also occur.

The ongoing research into bofanglutide offers promising insights into the management of type 2 diabetes and obesity. If approved, the biweekly injection could provide a valuable alternative for patients seeking effective treatment options with less frequent dosing requirements. Individuals considering GLP-1 therapy should consult their healthcare providers to discuss potential benefits and any concerns regarding side effects.